373 related articles for article (PubMed ID: 29653858)
1. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
Bonini S; Lambiase A; Rama P; Sinigaglia F; Allegretti M; Chao W; Mantelli F;
Ophthalmology; 2018 Sep; 125(9):1332-1343. PubMed ID: 29653858
[TBL] [Abstract][Full Text] [Related]
2. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.
Pflugfelder SC; Massaro-Giordano M; Perez VL; Hamrah P; Deng SX; Espandar L; Foster CS; Affeldt J; Seedor JA; Afshari NA; Chao W; Allegretti M; Mantelli F; Dana R
Ophthalmology; 2020 Jan; 127(1):14-26. PubMed ID: 31585826
[TBL] [Abstract][Full Text] [Related]
3. Topical treatment with nerve growth factor for neurotrophic keratitis.
Bonini S; Lambiase A; Rama P; Caprioglio G; Aloe L
Ophthalmology; 2000 Jul; 107(7):1347-51; discussion 1351-2. PubMed ID: 10889110
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial.
Ferrari MP; Mantelli F; Sacchetti M; Antonangeli MI; Cattani F; D'Anniballe G; Sinigaglia F; Ruffini PA; Lambiase A
BioDrugs; 2014 Jun; 28(3):275-83. PubMed ID: 24327173
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure Outcomes.
Beykin G; Stell L; Halim MS; Nuñez M; Popova L; Nguyen BT; Groth SL; Dennis A; Li Z; Atkins M; Khavari T; Wang SY; Chang R; Fisher AC; Sepah YJ; Goldberg JL
Am J Ophthalmol; 2022 Feb; 234():223-234. PubMed ID: 34780798
[TBL] [Abstract][Full Text] [Related]
6. Cenegermin: A Review in Neurotrophic Keratitis.
Deeks ED; Lamb YN
Drugs; 2020 Apr; 80(5):489-494. PubMed ID: 32185680
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.
Apfel SC; Schwartz S; Adornato BT; Freeman R; Biton V; Rendell M; Vinik A; Giuliani M; Stevens JC; Barbano R; Dyck PJ
JAMA; 2000 Nov; 284(17):2215-21. PubMed ID: 11056593
[TBL] [Abstract][Full Text] [Related]
8. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers.
Aifa A; Gueudry J; Portmann A; Delcampe A; Muraine M
Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8181-5. PubMed ID: 23150626
[TBL] [Abstract][Full Text] [Related]
9. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
10. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.
Yoon KC; You IC; Im SK; Jeong TS; Park YG; Choi J
Ophthalmology; 2007 Sep; 114(9):1637-42. PubMed ID: 17382396
[TBL] [Abstract][Full Text] [Related]
11. Cenegermin for the treatment of neurotrophic keratitis.
Sacchetti M; Bruscolini A; Lambiase A
Drugs Today (Barc); 2017 Nov; 53(11):585-595. PubMed ID: 29451275
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Evaluation of Corneal Nerves and Epithelial Healing After Treatment With Recombinant Nerve Growth Factor for Neurotrophic Keratopathy.
Mastropasqua L; Lanzini M; Dua HS; D' Uffizi A; Di Nicola M; Calienno R; Bondì J; Said DG; Nubile M
Am J Ophthalmol; 2020 Sep; 217():278-286. PubMed ID: 32387431
[TBL] [Abstract][Full Text] [Related]
13. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
14. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
Cursiefen C; Viaud E; Bock F; Geudelin B; Ferry A; Kadlecová P; Lévy M; Al Mahmood S; Colin S; Thorin E; Majo F; Frueh B; Wilhelm F; Meyer-Ter-Vehn T; Geerling G; Böhringer D; Reinhard T; Meller D; Pleyer U; Bachmann B; Seitz B
Ophthalmology; 2014 Sep; 121(9):1683-92. PubMed ID: 24811963
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops.
Sanchez-Avila RM; Merayo-Lloves J; Riestra AC; Fernandez-Vega Cueto L; Anitua E; Begoña L; Muruzabal F; Orive G
Int Ophthalmol; 2018 Jun; 38(3):1193-1204. PubMed ID: 28620707
[TBL] [Abstract][Full Text] [Related]
16. Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).
Hamrah P; Massaro-Giordano M; Schanzlin D; Holland E; Berdy G; Goisis G; Pasedis G; Mantelli F
Ophthalmol Ther; 2024 Feb; 13(2):553-570. PubMed ID: 38175466
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
Bruscolini A; Marenco M; Albanese GM; Lambiase A; Sacchetti M
Orphanet J Rare Dis; 2022 Feb; 17(1):57. PubMed ID: 35172847
[TBL] [Abstract][Full Text] [Related]
18. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
[TBL] [Abstract][Full Text] [Related]
19. A New Treatment for Recalcitrant Neurotrophic Keratopathy of Ocular Graft-Versus-Host Disease with Virus Infection.
Qu Y; Peng R; Hu B; Ma S; Liu Z; Gu S; Hong J
Ophthalmol Ther; 2024 Feb; 13(2):469-479. PubMed ID: 38057555
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
